Boehringer Ingelheim GmbH - Product Pipeline Review - 2016

  • ID: 3746939
  • Company Profile
  • 186 pages
  • Global Markets Direct
  • Boehringer Ingelheim GmbH
1 of 4
Boehringer Ingelheim GmbH - Product Pipeline Review - 2016

Summary

‘Boehringer Ingelheim GmbH - Product Pipeline Review - 2016’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Boehringer Ingelheim GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Boehringer Ingelheim GmbH
- The report provides overview of Boehringer Ingelheim GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Boehringer Ingelheim GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Boehringer Ingelheim GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Boehringer Ingelheim GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Boehringer Ingelheim GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Boehringer Ingelheim GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Boehringer Ingelheim GmbH Snapshot

Boehringer Ingelheim GmbH Overview

Key Information

Key Facts

Boehringer Ingelheim GmbH - Research and Development Overview

Key Therapeutic Areas

Boehringer Ingelheim GmbH - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Boehringer Ingelheim GmbH - Pipeline Products Glance

Boehringer Ingelheim GmbH - Late Stage Pipeline Products

Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products

Boehringer Ingelheim GmbH - Early Stage Pipeline Products

Boehringer Ingelheim GmbH - Drug Profiles

(empagliflozin + linagliptin)

(linagliptin + metformin hydrochloride ER)

(olodaterol hydrochloride + tiotropium bromide)

idarucizumab

(empagliflozin + metformin hydrochloride XR)

adalimumab biosimilar

afatinib dimaleate

bevacizumab biosimilar

empagliflozin

nintedanib

risankizumab

rituximab biosimilar

volasertib trihydrochloride

BI-1026706

BI-1361849

BI-144807

BI-409306

FX-125L

HM-61713

BI-836826

BI-836845

BI-836858

BI-1005273

BI-1060469

BI-113608

BI-416970

BI-425809

BI-443651

BI-655064

BI-655088

BI-655130

BI-685509

BI-836880

BI-836909

BI-853520

BI-860585

BI-894999

PXS-4728A

Small Molecule for Oncology

AR-116082

BI-113823

BI-1467335

BI-186908

BI-207524 Follow-Up

BI-703704

BI-882370

CNX-012

CNX-012570

linagliptin

Monoclonal Antibody for Ophthalmology

olcegepant

Small Molecule 2 for Oncology

Small Molecule 2 to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis

Small Molecule 3 for Oncology

Small Molecule for Respiratory Diseases

Small Molecule to Agonize Glucocorticoid Receptor for Inflammation

Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis

Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection

Small Molecules for Respiratory Disorders

Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy

Synthetic Peptide for CardioMetabolic Disease

Antibody for Oncology

BI-665915

Small Molecule for HIV

Small Molecule for HIV-1 Infection

Small Molecule to Agonize Glucocorticoid Receptor

Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders

Small Molecules for Oncology

Small Molecules for Schizophrenia

Small Molecules for Undisclosed Indication

Small Molecules to Inhibit K-Ras for Oncology

Small Molecules to Inhibit Kinases for Oncology

Synthetic Peptide to Agonize Glucagon and GLP-1 for Metabolic Disorders

Boehringer Ingelheim GmbH - Pipeline Analysis

Boehringer Ingelheim GmbH - Pipeline Products by Target

Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration

Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type

Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action

Boehringer Ingelheim GmbH - Recent Pipeline Updates

Boehringer Ingelheim GmbH - Dormant Projects

Boehringer Ingelheim GmbH - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Boehringer Ingelheim GmbH - Company Statement

Boehringer Ingelheim GmbH - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Boehringer Ingelheim GmbH, Key Information

Boehringer Ingelheim GmbH, Key Facts

Boehringer Ingelheim GmbH - Pipeline by Indication, 2016

Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016

Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016

Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016

Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016

Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2016

Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016

Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016

Boehringer Ingelheim GmbH - Pre-Registration, 2016

Boehringer Ingelheim GmbH - Phase III, 2016

Boehringer Ingelheim GmbH - Phase II, 2016

Boehringer Ingelheim GmbH - Phase I, 2016

Boehringer Ingelheim GmbH - Preclinical, 2016

Boehringer Ingelheim GmbH - Discovery, 2016

Boehringer Ingelheim GmbH - Pipeline by Target, 2016

Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016

Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016

Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2016

Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2016

Boehringer Ingelheim GmbH - Dormant Developmental Projects,2016

Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2016

Boehringer Ingelheim GmbH, Subsidiaries

List of Figures

Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2016

Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016

Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016

Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016

Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016

Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016

Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2016

Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016

Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016

Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll